4792

This disclosure relates to vectors carrying a modified MAD7 gene optimized for high expression in vertebrates, including  zebrafish and human cells.

Tangible property ready for use

Mad7 is a novel RNA-guided nuclease described by Inscripta with high potential for gene editing.  To our knowledge, there are no published reports of Mad7 nuclease activity in vertebrate organisms. The sequence of native Mad 7 is available through the company's website. ISU researchers optimized the Mad7 gene for use in vertebrates by introducing new codons and adding nuclear localization signals. The gene changes were designed to promote enhanced translation and nuclear importation of MAD7 aiming to facilitate DNA binding and subsequent  DNA cleavage in a gRNA dependent manner. Mad7 cleavage can induce single strand annealing repair for potentially targeting integrations. The modified gene of this disclosure has been extensively characterized in zebrafish. Validation in mammals has been accomplished in human cells. 

According to a 2019 BCC report titled "Genome Editing: Technologies and Global Markets", the global market for genome editing should grow from $1.4 billion in 2018 to $4.4 billion by 2023, with a compound annual growth rate (CAGR) of 25.7% for the period of 2018-2023. U.S. Market for genome editing should grow from $535 million in 2018 to $1.7 billion by 2023, with a CAGR of 26.6% within this period.

• Proof of concept in zebrafish and human cells

• Ready to use

This innovation provides an optimized Mad7 enzyme for use in vertebrates. The materials could be applied to research in a variety of fields engaged in gene-editing and other genome modifications.

Tangible Material